Geoffrey I. Shapiro

Broad Institute (US)

Research Areas

Discover Papers by Geoffrey I. Shapiro

Access 250+ million papers and cite this researcher's work with AI assistance

Try AnswerThis Free →

H-index

115

Publications

2037

Citations

57177

i10-index

387

Publications & Citations Over Time

Top Cited Publications

Want to find and read papers by this researcher? AnswerThis gives you instant access.

Title	Year	Citations
Anaplastic Lymphoma Kinase Inhibition in Non–Small...	2010	4491
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cel...	2014	1983
KRAS <sup>G12C</sup> Inhibition with Sotorasib in ...	2020	1652
BIBW2992, an irreversible EGFR/HER2 inhibitor high...	2008	1434
Activity and safety of crizotinib in patients with...	2012	1275
Activation of the PD-1 Pathway Contributes to Immu...	2013	1233
LKB1 modulates lung cancer differentiation and met...	2007	1061
Cyclin-Dependent Kinase Pathways As Targets for Ca...	2006	1020
Homologous Recombination Deficiency: Exploiting th...	2015	940
Targeting CDK4 and CDK6: From Discovery to Therapy	2015	928

Publications

1.
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Year: 2010Citations: 4491DOI: 10.1056/nejmoa1006448
2.
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
Year: 2014Citations: 1983DOI: 10.1056/nejmoa1406766
3.
KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors
Year: 2020Citations: 1652DOI: 10.1056/nejmoa1917239
4.
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Year: 2008Citations: 1434DOI: 10.1038/onc.2008.109
5.
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
Year: 2012Citations: 1275DOI: 10.1016/s1470-2045(12)70344-3
6.
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Year: 2013Citations: 1233DOI: 10.1158/2159-8290.cd-13-0310
7.
LKB1 modulates lung cancer differentiation and metastasis
Year: 2007Citations: 1061DOI: 10.1038/nature06030
8.
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Year: 2006Citations: 1020DOI: 10.1200/jco.2005.03.7689
9.
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Year: 2015Citations: 940DOI: 10.1158/2159-8290.cd-15-0714
10.
Targeting CDK4 and CDK6: From Discovery to Therapy
Year: 2015Citations: 928DOI: 10.1158/2159-8290.cd-15-0894

About Geoffrey I. Shapiro

Geoffrey I. Shapiro is a researcher with 2037 publications and 57177 citations. They are affiliated with Broad Institute. Their research focuses on . With an h-index of 115, they are among the top researchers in their field.

Citation Distribution

Distribution of citations across publications

Research Smarter

AnswerThis uses AI to help you search, understand, and cite research from Geoffrey I. Shapiro and 250M+ other papers.

AI-powered research assistance
Automatic citations and references
Advanced academic writing tools

Research Area Breakdown

Publication Types

Publication type data not available

Impact Metrics Over Time

Citations per publication by year